[{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hims","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hims","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hims \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hims \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Zuellig Pharma"},{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Vaccines \/ IQVIA"},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Digital Offering, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Digital Offering, LLC","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Digital Offering, LLC"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ IntelGenx"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Seattle Gummy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qilu Pharmaceutical \/ ECI Pharmaceuticals LLC","highestDevelopmentStatusID":"15","companyTruncated":"Qilu Pharmaceutical \/ ECI Pharmaceuticals LLC"},{"orgOrder":0,"company":"CTCBIO INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CTCBIO INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CTCBIO INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTCBIO INC \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emifarma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Emifarma \/ Mangoceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Emifarma \/ Mangoceuticals"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silodosin","moa":"||Adrenergic-alpha-1A receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dutasteride","moa":"||Cholestenone-5-alpha-reductase","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dongkook Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Urology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selexipag","moa":"||Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"||Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Cialis
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
